A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder

    Not Recruiting
  • participants needed
  • sponsor
    Astellas Pharma Inc
Updated on 20 June 2021
bipolar disorder
depressive symptoms


The purpose of this study is to evaluate the safety and effectiveness of quetiapine in actual clinical settings.


This is a post-marketing use-result survey study required for products in Japan. The investigator will register the patient who have been taking this product for the first time within 14 days after the start of treatment (inclusive of the start day). For each of the registered patients (including withdrawals and dropouts), the investigator will enter the survey data on the case report form.

Condition Endogenous depression, Depression, Bipolar Disorder
Treatment Quetiapine
Clinical Study IdentifierNCT03403790
SponsorAstellas Pharma Inc
Last Modified on20 June 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note